Ciliary neurotrophic factor (DrugBank: Ciliary neurotrophic factor)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 90 | 網膜色素変性症 | 4 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01530659 (ClinicalTrials.gov) | January 2012 | 19/1/2012 | Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis Pigmentosa | Photoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and Density | Retinitis Pigmentosa;Usher Syndrome Type 2;Usher Syndrome Type 3 | Drug: NT-501;Procedure: Sham | Neurotech Pharmaceuticals | University of California, San Francisco;FDA Office of Orphan Products Development | Unknown status | 18 Years | 55 Years | All | 30 | Phase 2 | United States |
| 2 | NCT00447993 (ClinicalTrials.gov) | January 2007 | 9/3/2007 | A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa | A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Acuity as the Primary Outcome | Retinitis Pigmentosa | Drug: NT-501 | Neurotech Pharmaceuticals | NULL | Completed | 18 Years | 68 Years | Both | 65 | Phase 2 | United States |
| 3 | NCT00447980 (ClinicalTrials.gov) | January 2007 | 9/3/2007 | A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa | A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Field Sensitivity as the Primary Outcome | Retinitis Pigmentosa | Drug: NT-501 | Neurotech Pharmaceuticals | NULL | Completed | 18 Years | 64 Years | Both | 68 | Phase 2 | United States |
| 4 | NCT00063765 (ClinicalTrials.gov) | June 2003 | 3/7/2003 | Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye | A Phase I Study of NT-501-10 and NT-501-6A.02, Implants of Encapsulated Human NTC-210 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Patients With Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Ciliary Neurotrophic Factor Implant NT-501 | National Eye Institute (NEI) | NULL | Completed | N/A | N/A | Both | 10 | Phase 1 | United States |